Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Public ClinicalTrials.gov record NCT00788073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study objective is to explore the efficacy, safety and tolerability of STX209 for treatment of irritability in subjects with FSX. We hypothesize that STX209 will improve irritability and other typical problem behaviors associated with fragile X syndrome. We also hypothesize that STX209 will be safe and well tolerated.
Study identification
- NCT ID
- NCT00788073
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years to 40 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2008 (Type not available)
- Primary completion
- Mar 2010 (Actual)
- Completion
- May 2010 (Actual)
- Last update posted
- May 6, 2013
2008 – 2010
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southwest Autism Research & Resource Center | Phoenix | Arizona | 85006 | — |
| University of California-Los Angeles Neuropsychiatric Institute | Los Angeles | California | 90024 | — |
| M.I.N.D. Institute | Sacramento | California | 95817 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Riley Hospital for Children | Indianapolis | Indiana | 46202 | — |
| Children's Hospital Boston | Boston | Massachusetts | 02115 | — |
| NYS Institute for Basic Research in Developmental Disabilities | Staten Island | New York | 10314 | — |
| University of North Carolina Neurosciences Hospital | Chapel Hill | North Carolina | 27514 | — |
| Suburban Research Associates | Media | Pennsylvania | 19063 | — |
| Vanderbilt Kennedy Center | Nashville | Tennessee | 37203 | — |
| Red Oaks Psychiatry Associates, P.A. | Houston | Texas | 77090 | — |
| Seattle Children's Hospital | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00788073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2013 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00788073 live on ClinicalTrials.gov.